» Articles » PMID: 25488983

Heterozygous Splice Mutation in PIK3R1 Causes Human Immunodeficiency with Lymphoproliferation Due to Dominant Activation of PI3K

Abstract

Class IA phosphatidylinositol 3-kinases (PI3K), which generate PIP3 as a signal for cell growth and proliferation, exist as an intracellular complex of a catalytic subunit bound to a regulatory subunit. We and others have previously reported that heterozygous mutations in PIK3CD encoding the p110δ catalytic PI3K subunit cause a unique disorder termed p110δ-activating mutations causing senescent T cells, lymphadenopathy, and immunodeficiency (PASLI) disease. We report four patients from three families with a similar disease who harbor a recently reported heterozygous splice site mutation in PIK3R1, which encodes the p85α, p55α, and p50α regulatory PI3K subunits. These patients suffer from recurrent sinopulmonary infections and lymphoproliferation, exhibit hyperactive PI3K signaling, and have prominent expansion and skewing of peripheral blood CD8(+) T cells toward terminally differentiated senescent effector cells with short telomeres. The PIK3R1 splice site mutation causes skipping of an exon, corresponding to loss of amino acid residues 434-475 in the inter-SH2 domain. The mutant p85α protein is expressed at low levels in patient cells and activates PI3K signaling when overexpressed in T cells from healthy subjects due to qualitative and quantitative binding changes in the p85α-p110δ complex and failure of the C-terminal region to properly inhibit p110δ catalytic activity.

Citing Articles

Molecular assessment of splicing variants in a cohort of patients with inborn errors of immunity: methodological approach and interpretation remarks.

Miguel Berenguel L, Gianelli C, Matas Perez E, Del Rosal T, Mendez Echevarria A, Robles Marhuenda A Front Immunol. 2025; 15:1499415.

PMID: 39944559 PMC: 11814461. DOI: 10.3389/fimmu.2024.1499415.


Piloting an automated query and scoring system to facilitate APDS patient identification from health systems.

FitzPatrick A, Chin A, Nirenberg S, Cunningham-Rundles C, Sacco K, Perlmutter J Front Immunol. 2025; 15:1508780.

PMID: 39906746 PMC: 11790479. DOI: 10.3389/fimmu.2024.1508780.


Value contribution of leniolisib in the Treatment of Activated PI3Kδ syndrome (APDS) in Spain using Multi-Criteria Decision Analysis (MCDA).

Abad M, Alerany C, Gonzalez L, Neth O, Payares-Herrera C, Rodriguez-Gallego C Glob Reg Health Technol Assess. 2025; 12:9-15.

PMID: 39882388 PMC: 11776101. DOI: 10.33393/grhta.2025.3199.


Paradoxical dominant negative activity of an immunodeficiency-associated activating variant.

Tomlinson P, Knox R, Perisic O, Su H, Brierley G, Williams R Elife. 2025; 13.

PMID: 39835783 PMC: 11750134. DOI: 10.7554/eLife.94420.


Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives.

IJspeert H, Dalm V, van Zelm M, Edwards E Immunother Adv. 2024; 4(1):ltae009.

PMID: 39679264 PMC: 11638974. DOI: 10.1093/immadv/ltae009.


References
1.
Deau M, Heurtier L, Frange P, Suarez F, Bole-Feysot C, Nitschke P . A human immunodeficiency caused by mutations in the PIK3R1 gene. J Clin Invest. 2014; 124(9):3923-8. PMC: 4153704. DOI: 10.1172/JCI75746. View

2.
Crank M, Grossman J, Moir S, Pittaluga S, Buckner C, Kardava L . Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility. J Clin Immunol. 2014; 34(3):272-6. PMC: 4159085. DOI: 10.1007/s10875-014-0012-9. View

3.
Keppler-Noreuil K, Sapp J, Lindhurst M, Parker V, Blumhorst C, Darling T . Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am J Med Genet A. 2014; 164A(7):1713-33. PMC: 4320693. DOI: 10.1002/ajmg.a.36552. View

4.
Barcena C, Quesada V, De Sandre-Giovannoli A, Puente D, Fernandez-Toral J, Sigaudy S . Exome sequencing identifies a novel mutation in PIK3R1 as the cause of SHORT syndrome. BMC Med Genet. 2014; 15:51. PMC: 4022398. DOI: 10.1186/1471-2350-15-51. View

5.
Kahl B, Spurgeon S, Furman R, Flinn I, Coutre S, Brown J . A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014; 123(22):3398-405. PMC: 4260977. DOI: 10.1182/blood-2013-11-537555. View